zedie.wordpress.com
SAVOR-TIMI 53 raises bar for CV outcome trials in diabetes.
When added to standard care in patients with type 2 diabetes at high CV risk, saxagliptin neither reduced nor increased risk for ischemic events, according to results from the SAVOR-TIMI 53 trial. …